{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T12:40:55Z","timestamp":1784896855044,"version":"3.55.0"},"reference-count":72,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2020,4,30]],"date-time":"2020-04-30T00:00:00Z","timestamp":1588204800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2020,4,30]],"date-time":"2020-04-30T00:00:00Z","timestamp":1588204800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Pharmacokinet"],"published-print":{"date-parts":[[2020,9]]},"DOI":"10.1007\/s40262-020-00892-0","type":"journal-article","created":{"date-parts":[[2020,4,30]],"date-time":"2020-04-30T06:03:42Z","timestamp":1588226622000},"page":"1071-1084","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":29,"title":["Preclinical Pharmacokinetic\/Pharmacodynamic Studies and Clinical Trials in the Drug Development Process of EMA-Approved Antibacterial Agents: A Review"],"prefix":"10.1007","volume":"59","author":[{"given":"Anselm","family":"Jorda","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"Zeitlinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,4,30]]},"reference":[{"key":"892_CR1","volume-title":"Global antimicrobial resistance surveillance system (GLASS) report: early implementation 2016\u20132017","author":"World Health Organization","year":"2017","unstructured":"World Health Organization. Global antimicrobial resistance surveillance system (GLASS) report: early implementation 2016\u20132017. Geneva: World Health Organization; 2017."},{"issue":"10100","key":"892_CR2","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1016\/S0140-6736(17)32152-9","volume":"390","author":"Global Health Metrics","year":"2017","unstructured":"Global Health Metrics. Global, regional, and national age-sex specific mortality for 264 causes of death, 1980\u20132016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet. 2017;390(10100):1151\u2013210.","journal-title":"Lancet"},{"key":"892_CR3","volume-title":"European Medicines Agency: 20th anniversary book","author":"K Woods","year":"2015","unstructured":"Woods K, Wathion N. European Medicines Agency: 20th anniversary book. London: Core Media Services UK Ltd.; 2015."},{"key":"892_CR4","unstructured":"EMA. Authorisation of medicines. Available from: https:\/\/www.ema.europa.eu\/en\/about-us\/what-we-do\/authorisation-medicines. Accessed 8 Nov 2019."},{"key":"892_CR5","volume-title":"Guideline on the evaluation of medicinal products indicated for the treatment of bacterial infections: revision 3 (EMA\/844951\/2018)","author":"EMA-CHMP","year":"2018","unstructured":"EMA-CHMP. Guideline on the evaluation of medicinal products indicated for the treatment of bacterial infections: revision 3 (EMA\/844951\/2018). London: European Medicines Agency; 2018."},{"key":"892_CR6","volume-title":"Addendum to the guideline on the evaluation of medicinal products indicated for treatment of bacterial infections (EMA\/CHMP\/351889\/2013))","author":"EMA-CHMP","year":"2013","unstructured":"EMA-CHMP. Addendum to the guideline on the evaluation of medicinal products indicated for treatment of bacterial infections (EMA\/CHMP\/351889\/2013). London: European Medicines Agency; 2013."},{"key":"892_CR7","volume-title":"Guideline on the use of pharmacokinetics and pharmacodynamics in the development of antimicrobial medicinal products (EMA\/CHMP\/594085\/2015)","author":"EMA-CHMP","year":"2016","unstructured":"EMA-CHMP. Guideline on the use of pharmacokinetics and pharmacodynamics in the development of antimicrobial medicinal products (EMA\/CHMP\/594085\/2015). London: European Medicines Agency; 2016."},{"key":"892_CR8","unstructured":"EMA. European public assessment reports: background and context. Available from: https:\/\/www.ema.europa.eu\/en\/medicines\/what-we-publish-when\/european-public-assessment-reports-background-context. Accessed 11 Oct 2019."},{"issue":"4","key":"892_CR9","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1016\/s0924-8579(02)00022-5","volume":"19","author":"D Andes","year":"2002","unstructured":"Andes D, Craig WA. Animal model pharmacokinetics and pharmacodynamics: a critical review. Int J Antimicrob Agents. 2002;19(4):261\u20138. https:\/\/doi.org\/10.1016\/s0924-8579(02)00022-5.","journal-title":"Int J Antimicrob Agents"},{"issue":"24","key":"892_CR10","doi-asserted-by":"publisher","first-page":"6390","DOI":"10.1016\/j.bmc.2016.11.008","volume":"24","author":"M Zhao","year":"2016","unstructured":"Zhao M, Lepak AJ, Andes DR. Animal models in the pharmacokinetic\/pharmacodynamic evaluation of antimicrobial agents. Bioorg Med Chem. 2016;24(24):6390\u2013400. https:\/\/doi.org\/10.1016\/j.bmc.2016.11.008.","journal-title":"Bioorg Med Chem"},{"key":"892_CR11","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.coph.2017.09.004","volume":"36","author":"DR Andes","year":"2017","unstructured":"Andes DR, Lepak AJ. In vivo infection models in the pre-clinical pharmacokinetic\/pharmacodynamic evaluation of antimicrobial agents. Curr Opin Pharmacol. 2017;36:94\u20139. https:\/\/doi.org\/10.1016\/j.coph.2017.09.004.","journal-title":"Curr Opin Pharmacol"},{"issue":"5","key":"892_CR12","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1007\/s11095-016-1856-x","volume":"33","author":"AN Kristoffersson","year":"2016","unstructured":"Kristoffersson AN, David-Pierson P, Parrott NJ, Kuhlmann O, Lave T, Friberg LE, et al. Simulation-based evaluation of PK\/PD indices for meropenem across patient groups and experimental designs. Pharm Res. 2016;33(5):1115\u201325. https:\/\/doi.org\/10.1007\/s11095-016-1856-x.","journal-title":"Pharm Res"},{"issue":"7","key":"892_CR13","doi-asserted-by":"publisher","first-page":"3067","DOI":"10.1128\/AAC.01433-10","volume":"55","author":"MA Zeitlinger","year":"2011","unstructured":"Zeitlinger MA, Derendorf H, Mouton JW, Cars O, Craig WA, Andes D, et al. Protein binding: do we ever learn? Antimicrob Agents Chemother. 2011;55(7):3067\u201374. https:\/\/doi.org\/10.1128\/AAC.01433-10.","journal-title":"Antimicrob Agents Chemother"},{"issue":"5","key":"892_CR14","doi-asserted-by":"publisher","first-page":"1340","DOI":"10.1093\/jac\/dkx541","volume":"73","author":"TW Felton","year":"2018","unstructured":"Felton TW, Ogungbenro K, Boselli E, Hope WW, Rodvold KA. Comparison of piperacillin exposure in the lungs of critically ill patients and healthy volunteers. J Antimicrob Chemother. 2018;73(5):1340\u20137. https:\/\/doi.org\/10.1093\/jac\/dkx541.","journal-title":"J Antimicrob Chemother"},{"issue":"3","key":"892_CR15","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1016\/j.ijantimicag.2018.11.011","volume":"53","author":"AJ Heffernan","year":"2019","unstructured":"Heffernan AJ, Sime FB, Lipman J, Dhanani J, Andrews K, Ellwood D, et al. Intrapulmonary pharmacokinetics of antibiotics used to treat nosocomial pneumonia caused by Gram-negative bacilli: a systematic review. Int J Antimicrob Agents. 2019;53(3):234\u201345. https:\/\/doi.org\/10.1016\/j.ijantimicag.2018.11.011.","journal-title":"Int J Antimicrob Agents"},{"issue":"10","key":"892_CR16","doi-asserted-by":"publisher","first-page":"5151","DOI":"10.1128\/AAC.00778-13","volume":"57","author":"R Schwameis","year":"2013","unstructured":"Schwameis R, Erdogan-Yildirim Z, Manafi M, Zeitlinger MA, Strommer S, Sauermann R. Effect of pulmonary surfactant on antimicrobial activity in vitro. Antimicrob Agents Chemother. 2013;57(10):5151\u20134. https:\/\/doi.org\/10.1128\/AAC.00778-13.","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"892_CR17","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1097\/QCO.0000000000000418","volume":"31","author":"R Nau","year":"2018","unstructured":"Nau R, Seele J, Djukic M, Eiffert H. Pharmacokinetics and pharmacodynamics of antibiotics in central nervous system infections. Curr Opin Infect Dis. 2018;31(1):57\u201368. https:\/\/doi.org\/10.1097\/QCO.0000000000000418.","journal-title":"Curr Opin Infect Dis"},{"issue":"3","key":"892_CR18","doi-asserted-by":"publisher","first-page":"340","DOI":"10.4103\/ijmm.IJMM_17_278","volume":"35","author":"GSR Hoo","year":"2017","unstructured":"Hoo GSR, Liew YX, Kwa AL. Optimisation of antimicrobial dosing based on pharmacokinetic and pharmacodynamic principles. Indian J Med Microbiol. 2017;35(3):340\u20136. https:\/\/doi.org\/10.4103\/ijmm.IJMM_17_278.","journal-title":"Indian J Med Microbiol"},{"issue":"1","key":"892_CR19","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1128\/AAC.01269-15","volume":"60","author":"J Berkhout","year":"2016","unstructured":"Berkhout J, Melchers MJ, van Mil AC, Seyedmousavi S, Lagarde CM, Schuck VJ, et al. Pharmacodynamics of ceftazidime and avibactam in neutropenic mice with thigh or lung infection. Antimicrob Agents Chemother. 2016;60(1):368\u201375. https:\/\/doi.org\/10.1128\/AAC.01269-15.","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"892_CR20","doi-asserted-by":"publisher","first-page":"e01659","DOI":"10.1128\/AAC.01659-18","volume":"63","author":"DC Griffith","year":"2018","unstructured":"Griffith DC, Sabet M, Tarazi Z, Lomovskaya O, Dudley MN. Pharmacokinetics\/pharmacodynamics of vaborbactam, a novel beta-lactamase inhibitor, in combination with meropenem. Antimicrob Agents Chemother. 2018;63(1):e01659\u2013e1718. https:\/\/doi.org\/10.1128\/AAC.01659-18.","journal-title":"Antimicrob Agents Chemother"},{"issue":"12 Suppl. 4","key":"892_CR21","doi-asserted-by":"publisher","first-page":"S23","DOI":"10.2146\/090087d","volume":"66","author":"RC Owens Jr","year":"2009","unstructured":"Owens RC Jr, Shorr AF. Rational dosing of antimicrobial agents: pharmacokinetic and pharmacodynamic strategies. Am J Health Syst Pharm. 2009;66(12 Suppl. 4):S23\u201330. https:\/\/doi.org\/10.2146\/090087d.","journal-title":"Am J Health Syst Pharm"},{"issue":"11","key":"892_CR22","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1007\/s40262-019-00791-z","volume":"58","author":"CD Sumi","year":"2019","unstructured":"Sumi CD, Heffernan AJ, Lipman J, Roberts JA, Sime FB. What antibiotic exposures are required to suppress the emergence of resistance for Gram-negative bacteria? A systematic review. Clin Pharmacokinet. 2019;58(11):1407\u201343. https:\/\/doi.org\/10.1007\/s40262-019-00791-z.","journal-title":"Clin Pharmacokinet"},{"key":"892_CR23","unstructured":"US FDA. Step 3: clinical research. 2018. Available from: https:\/\/www.fda.gov\/patients\/drug-development-process\/step-3-clinical-research#Clinical_Research_Phase_Studies. Accessed 11 Oct 2019."},{"key":"892_CR24","volume-title":"E8: general considerations for clinical trials: Step 5 (CPMP\/ICH\/291\/95)","author":"EMA-ICH","year":"1998","unstructured":"EMA-ICH. E8: general considerations for clinical trials: Step 5 (CPMP\/ICH\/291\/95). London: European Medicines Agency; 1998."},{"issue":"4","key":"892_CR25","doi-asserted-by":"publisher","first-page":"331","DOI":"10.2515\/therapie\/2011046","volume":"66","author":"M Bamberger","year":"2011","unstructured":"Bamberger M, Moore N, Lechat P. How to improve the clinical development paradigm and its division into phases I, II and III. Therapie. 2011;66(4):331\u2013334, 27-30. https:\/\/doi.org\/10.2515\/therapie\/2011046.","journal-title":"Therapie"},{"key":"892_CR26","doi-asserted-by":"publisher","first-page":"148","DOI":"10.3389\/fmed.2019.00148","volume":"6","author":"G Nicotera","year":"2019","unstructured":"Nicotera G, Sferrazza G, Serafino A, Pierimarchi P. The iterative development of medicines through the European Medicine Agency's adaptive pathway approach. Front Med (Lausanne). 2019;6:148. https:\/\/doi.org\/10.3389\/fmed.2019.00148.","journal-title":"Front Med (Lausanne)"},{"issue":"5","key":"892_CR27","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1016\/j.mib.2003.08.003","volume":"6","author":"SJ Projan","year":"2003","unstructured":"Projan SJ. Why is big Pharma getting out of antibacterial drug discovery? Curr Opin Microbiol. 2003;6(5):427\u201330.","journal-title":"Curr Opin Microbiol"},{"key":"892_CR28","unstructured":"US FDA. Generating antibiotic incentives now. Available from: https:\/\/www.fda.gov\/media\/110982\/download. Accessed 17 Apr 2020."},{"key":"892_CR29","unstructured":"European Medicine Agency. Medicines. Available from: https:\/\/www.ema.europa.eu\/en\/medicines. Accessed 3 Oct 2019."},{"key":"892_CR30","unstructured":"CenterWatch. FDA approved drugs. Available from: https:\/\/www.centerwatch.com\/drug-information\/fda-approvals\/. Accessed 3 Oct 2019."},{"key":"892_CR31","unstructured":"US FDA. FDA-approved drug products. Available from: https:\/\/www.accessdata.fda.gov\/scripts\/cder\/daf\/. Accessed 17 Apr 2020."},{"key":"892_CR32","unstructured":"US FDA. New drugs at FDA: CDER\u2019s new molecular entities and new therapeutic biological products. 2018. Available from: https:\/\/www.fda.gov\/drugs\/development-approval-process-drugs\/new-drugs-fda-cders-new-molecular-entities-and-new-therapeutic-biological-products. Accessed 17 Apr 2020."},{"key":"892_CR33","volume-title":"Applications for new human medicines under evaluation by the Committee for Medicinal Products for Human Use","author":"EMA","year":"2019","unstructured":"EMA. Applications for new human medicines under evaluation by the Committee for Medicinal Products for Human Use. Amsterdam: European Medicines Agency; 2019."},{"issue":"1","key":"892_CR34","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1128\/AAC.49.1.276-280.2005","volume":"49","author":"D Maglio","year":"2005","unstructured":"Maglio D, Banevicius MA, Sutherland C, Babalola C, Nightingale CH, Nicolau DP. Pharmacodynamic profile of ertapenem against Klebsiella pneumoniae and Escherichia coli in a murine thigh model. Antimicrob Agents Chemother. 2005;49(1):276\u201380. https:\/\/doi.org\/10.1128\/AAC.49.1.276-280.2005.","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"892_CR35","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1128\/AAC.49.1.188-194.2005","volume":"49","author":"PR Tessier","year":"2005","unstructured":"Tessier PR, Mattoes HM, Dandekar PK, Nightingale CH, Nicolau DP. Pharmacodynamic profile of telithromycin against macrolide- and fluoroquinolone-resistant Streptococcus pneumoniae in a neutropenic mouse thigh model. Antimicrob Agents Chemother. 2005;49(1):188\u201394. https:\/\/doi.org\/10.1128\/AAC.49.1.188-194.2005.","journal-title":"Antimicrob Agents Chemother"},{"issue":"7","key":"892_CR36","doi-asserted-by":"publisher","first-page":"2756","DOI":"10.1128\/AAC.01678-08","volume":"53","author":"AM Nicasio","year":"2009","unstructured":"Nicasio AM, Crandon JL, Nicolau DP. In vivo pharmacodynamic profile of tigecycline against phenotypically diverse Escherichia coli and Klebsiella pneumoniae isolates. Antimicrob Agents Chemother. 2009;53(7):2756\u201361. https:\/\/doi.org\/10.1128\/AAC.01678-08.","journal-title":"Antimicrob Agents Chemother"},{"key":"892_CR37","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.mib.2019.06.004","volume":"51","author":"SJ Dunn","year":"2019","unstructured":"Dunn SJ, Connor C, McNally A. The evolution and transmission of multi-drug resistant Escherichia coli and Klebsiella pneumoniae: the complexity of clones and plasmids. Curr Opin Microbiol. 2019;51:51\u20136. https:\/\/doi.org\/10.1016\/j.mib.2019.06.004.","journal-title":"Curr Opin Microbiol"},{"key":"892_CR38","doi-asserted-by":"publisher","first-page":"2379","DOI":"10.2147\/DDDT.S110946","volume":"10","author":"JA Hidalgo","year":"2016","unstructured":"Hidalgo JA, Vinluan CM, Antony N. Ceftazidime\/avibactam: a novel cephalosporin\/nonbeta-lactam beta-lactamase inhibitor for the treatment of complicated urinary tract infections and complicated intra-abdominal infections. Drug Des Dev Ther. 2016;10:2379\u201386. https:\/\/doi.org\/10.2147\/DDDT.S110946.","journal-title":"Drug Des Dev Ther"},{"issue":"11","key":"892_CR39","doi-asserted-by":"publisher","first-page":"5548","DOI":"10.1128\/AAC.01288-13","volume":"57","author":"JA Sutcliffe","year":"2013","unstructured":"Sutcliffe JA, O'Brien W, Fyfe C, Grossman TH. Antibacterial activity of eravacycline (TP-434), a novel fluorocycline, against hospital and community pathogens. Antimicrob Agents Chemother. 2013;57(11):5548\u201358. https:\/\/doi.org\/10.1128\/AAC.01288-13.","journal-title":"Antimicrob Agents Chemother"},{"issue":"6","key":"892_CR40","doi-asserted-by":"publisher","first-page":"3840","DOI":"10.1128\/AAC.00436-16","volume":"60","author":"DM Livermore","year":"2016","unstructured":"Livermore DM, Mushtaq S, Warner M, Woodford N. In vitro activity of eravacycline against carbapenem-resistant Enterobacteriaceae and Acinetobacter baumannii. Antimicrob Agents Chemother. 2016;60(6):3840\u20134. https:\/\/doi.org\/10.1128\/AAC.00436-16.","journal-title":"Antimicrob Agents Chemother"},{"issue":"4","key":"892_CR41","doi-asserted-by":"publisher","first-page":"e02327","DOI":"10.1128\/AAC.02327-17","volume":"62","author":"MA Pfaller","year":"2018","unstructured":"Pfaller MA, Huband MD, Shortridge D, Flamm RK. Surveillance of omadacycline activity tested against clinical isolates from the United States and Europe as part of the 2016 SENTRY Antimicrobial Surveillance Program. Antimicrob Agents Chemother. 2018;62(4):e02327\u2013e2417. https:\/\/doi.org\/10.1128\/AAC.02327-17.","journal-title":"Antimicrob Agents Chemother"},{"key":"892_CR42","volume-title":"Value-based strategies for encouriging new development of antimicrobial drugs","author":"GW Daniel","year":"2017","unstructured":"Daniel GW, McClellan MB, Schneider M, Qian J, Lavezzari G, deGraffenreid E. Value-based strategies for encouriging new development of antimicrobial drugs. Washington, D.C.: Duke-Margolis Center for Health Policy; 2017."},{"issue":"2","key":"892_CR43","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1111\/bph.13895","volume":"175","author":"W Zheng","year":"2018","unstructured":"Zheng W, Sun W, Simeonov A. Drug repurposing screens and synergistic drug-combinations for infectious diseases. Br J Pharmacol. 2018;175(2):181\u201391. https:\/\/doi.org\/10.1111\/bph.13895.","journal-title":"Br J Pharmacol"},{"issue":"9\u201310","key":"892_CR44","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1016\/j.drudis.2011.12.018","volume":"17","author":"F Zhang","year":"2012","unstructured":"Zhang F, Xue J, Shao J, Jia L. Compilation of 222 drugs' plasma protein binding data and guidance for study designs. Drug Discov Today. 2012;17(9\u201310):475\u201385. https:\/\/doi.org\/10.1016\/j.drudis.2011.12.018.","journal-title":"Drug Discov Today"},{"issue":"4","key":"892_CR45","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1093\/jac\/dkv442","volume":"71","author":"M Zeitlinger","year":"2016","unstructured":"Zeitlinger M, Schwameis R, Burian A, Burian B, Matzneller P, Muller M, et al. Simultaneous assessment of the pharmacokinetics of a pleuromutilin, lefamulin, in plasma, soft tissues and pulmonary epithelial lining fluid. J Antimicrob Chemother. 2016;71(4):1022\u20136. https:\/\/doi.org\/10.1093\/jac\/dkv442.","journal-title":"J Antimicrob Chemother"},{"issue":"5","key":"892_CR46","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1016\/j.jcf.2008.03.007","volume":"7","author":"PM Farrell","year":"2008","unstructured":"Farrell PM. The prevalence of cystic fibrosis in the European Union. J Cyst Fibros. 2008;7(5):450\u20133. https:\/\/doi.org\/10.1016\/j.jcf.2008.03.007.","journal-title":"J Cyst Fibros"},{"key":"892_CR47","first-page":"38","volume":"7","author":"M Kosov","year":"2015","unstructured":"Kosov M, Riefler J, Belotserkovskiy M. Community-acquired bacterial pneumonia: a challenging diagnosis in clinical trials. J Clin Stud. 2015;7:38\u201340.","journal-title":"J Clin Stud"},{"issue":"6","key":"892_CR48","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1111\/bjh.14504","volume":"176","author":"RK Hills","year":"2017","unstructured":"Hills RK. Non-inferiority trials: no better? No worse? No change? No pain? Br J Haematol. 2017;176(6):883\u20137. https:\/\/doi.org\/10.1111\/bjh.14504.","journal-title":"Br J Haematol"},{"issue":"Suppl. 3","key":"892_CR49","doi-asserted-by":"publisher","first-page":"S108","DOI":"10.1086\/591390","volume":"47","author":"TR Fleming","year":"2008","unstructured":"Fleming TR, Powers JH. Issues in noninferiority trials: the evidence in community-acquired pneumonia. Clin Infect Dis. 2008;47(Suppl. 3):S108\u2013S120120. https:\/\/doi.org\/10.1086\/591390.","journal-title":"Clin Infect Dis"},{"issue":"3","key":"892_CR50","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1002\/sim.2855","volume":"27","author":"TR Fleming","year":"2008","unstructured":"Fleming TR. Current issues in non-inferiority trials. Stat Med. 2008;27(3):317\u201332. https:\/\/doi.org\/10.1002\/sim.2855.","journal-title":"Stat Med"},{"issue":"9602","key":"892_CR51","doi-asserted-by":"publisher","first-page":"1875","DOI":"10.1016\/s0140-6736(07)61604-3","volume":"370","author":"S Garattini","year":"2007","unstructured":"Garattini S, Bertele V. Non-inferiority trials are unethical because they disregard patients' interests. Lancet. 2007;370(9602):1875\u20137. https:\/\/doi.org\/10.1016\/s0140-6736(07)61604-3.","journal-title":"Lancet"},{"key":"892_CR52","volume-title":"Model list of essential medicines, 21st list","author":"WHO","year":"2019","unstructured":"WHO. Model list of essential medicines, 21st list. Geneva: World Health Organization; 2019."},{"issue":"3","key":"892_CR53","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1016\/S1473-3099(17)30747-8","volume":"18","author":"A Torres","year":"2018","unstructured":"Torres A, Zhong N, Pachl J, Timsit JF, Kollef M, Chen Z, et al. Ceftazidime-avibactam versus meropenem in nosocomial pneumonia, including ventilator-associated pneumonia (REPROVE): a randomised, double-blind, phase 3 non-inferiority trial. Lancet Infect Dis. 2018;18(3):285\u201395. https:\/\/doi.org\/10.1016\/S1473-3099(17)30747-8.","journal-title":"Lancet Infect Dis"},{"issue":"6","key":"892_CR54","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1016\/S1473-3099(16)30004-4","volume":"16","author":"Y Carmeli","year":"2016","unstructured":"Carmeli Y, Armstrong J, Laud PJ, Newell P, Stone G, Wardman A, et al. Ceftazidime-avibactam or best available therapy in patients with ceftazidime-resistant Enterobacteriaceae and Pseudomonas aeruginosa complicated urinary tract infections or complicated intra-abdominal infections (REPRISE): a randomised, pathogen-directed, phase 3 study. Lancet Infect Dis. 2016;16(6):661\u201373. https:\/\/doi.org\/10.1016\/S1473-3099(16)30004-4.","journal-title":"Lancet Infect Dis"},{"key":"892_CR55","first-page":"007","volume":"S1","author":"J Cadwell","year":"2012","unstructured":"Cadwell J. The hollow fiber infection model for antimicrobial pharmacodynamics and pharmacokinetics. Adv Pharmacoepidem Drug Safety. 2012;S1:007.","journal-title":"Adv Pharmacoepidem Drug Safety"},{"issue":"5","key":"892_CR56","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1016\/j.mib.2013.06.010","volume":"16","author":"T Velkov","year":"2013","unstructured":"Velkov T, Bergen PJ, Lora-Tamayo J, Landersdorfer CB, Li J. PK\/PD models in antibacterial development. Curr Opin Microbiol. 2013;16(5):573\u20139. https:\/\/doi.org\/10.1016\/j.mib.2013.06.010.","journal-title":"Curr Opin Microbiol"},{"issue":"4","key":"892_CR57","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1007\/s40121-018-0214-1","volume":"7","author":"RG Wunderink","year":"2018","unstructured":"Wunderink RG, Giamarellos-Bourboulis EJ, Rahav G, Mathers AJ, Bassetti M, Vazquez J, et al. Effect and safety of meropenem-vaborbactam versus best-available therapy in patients with carbapenem-resistant Enterobacteriaceae infections: the TANGO II randomized clinical trial. Infect Dis Ther. 2018;7(4):439\u201355. https:\/\/doi.org\/10.1007\/s40121-018-0214-1.","journal-title":"Infect Dis Ther"},{"key":"892_CR58","volume-title":"Global priority list of antibiotic-resistant bacteria to guide research, discovery, and development of new antibiotics","author":"WHO","year":"2017","unstructured":"WHO. Global priority list of antibiotic-resistant bacteria to guide research, discovery, and development of new antibiotics. Geneva: World Health Organization; 2017."},{"issue":"12","key":"892_CR59","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.1016\/S1473-3099(19)30403-7","volume":"19","author":"MH Kollef","year":"2019","unstructured":"Kollef MH, Novacek M, Kivistik U, Rea-Neto A, Shime N, Martin-Loeches I, et al. Ceftolozane-tazobactam versus meropenem for treatment of nosocomial pneumonia (ASPECT-NP): a randomised, controlled, double-blind, phase 3, non-inferiority trial. Lancet Infect Dis. 2019;19(12):1299\u2013311. https:\/\/doi.org\/10.1016\/S1473-3099(19)30403-7.","journal-title":"Lancet Infect Dis"},{"issue":"6","key":"892_CR60","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1056\/NEJMoa1800201","volume":"380","author":"R Stets","year":"2019","unstructured":"Stets R, Popescu M, Gonong JR, Mitha I, Nseir W, Madej A, et al. Omadacycline for community-acquired bacterial pneumonia. N Engl J Med. 2019;380(6):517\u201327. https:\/\/doi.org\/10.1056\/NEJMoa1800201.","journal-title":"N Engl J Med"},{"issue":"5","key":"892_CR61","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1177\/2049936117723228","volume":"4","author":"A Pulido-Cejudo","year":"2017","unstructured":"Pulido-Cejudo A, Guzman-Gutierrez M, Jalife-Montano A, Ortiz-Covarrubias A, Martinez-Ordaz JL, Noyola-Villalobos HF, et al. Management of acute bacterial skin and skin structure infections with a focus on patients at high risk of treatment failure. Ther Adv Infect Dis. 2017;4(5):143\u201361. https:\/\/doi.org\/10.1177\/2049936117723228.","journal-title":"Ther Adv Infect Dis"},{"key":"892_CR62","volume-title":"Guidance for industry: acute bacterial skin and skin structure infections: developing drugs for treatment","author":"US FDA","year":"2013","unstructured":"US FDA. Guidance for industry: acute bacterial skin and skin structure infections: developing drugs for treatment. Silver Spring: US Food and Drug Administration; 2013."},{"issue":"Suppl. 3","key":"892_CR63","doi-asserted-by":"publisher","first-page":"iii19","DOI":"10.1093\/jac\/dkr096","volume":"66","author":"TM File Jr","year":"2011","unstructured":"File TM Jr, Low DE, Eckburg PB, Talbot GH, Friedland HD, Lee J, et al. FOCUS 1: a randomized, double-blinded, multicentre, phase III trial of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in community-acquired pneumonia. J Antimicrob Chemother. 2011;66(Suppl. 3):iii19\u2013iii32. https:\/\/doi.org\/10.1093\/jac\/dkr096.","journal-title":"J Antimicrob Chemother."},{"issue":"Suppl. 3","key":"892_CR64","doi-asserted-by":"publisher","first-page":"iii33","DOI":"10.1093\/jac\/dkr097","volume":"66","author":"DE Low","year":"2011","unstructured":"Low DE, File TM Jr, Eckburg PB, Talbot GH, David Friedland H, Lee J, et al. FOCUS 2: a randomized, double-blinded, multicentre, phase III trial of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in community-acquired pneumonia. J Antimicrob Chemother. 2011;66(Suppl. 3):iii33\u2013iii44. https:\/\/doi.org\/10.1093\/jac\/dkr097.","journal-title":"J Antimicrob Chemother."},{"issue":"8","key":"892_CR65","doi-asserted-by":"publisher","first-page":"1076","DOI":"10.1086\/339543","volume":"34","author":"G Ortiz-Ruiz","year":"2002","unstructured":"Ortiz-Ruiz G, Caballero-Lopez J, Friedland IR, Woods GL, Carides A, Protocol 018 Ertapenem Community-Acquired Pneumonia Study G. A study evaluating the efficacy, safety, and tolerability of ertapenem versus ceftriaxone for the treatment of community-acquired pneumonia in adults. Clin Infect Dis. 2002;34(8):1076\u201383. https:\/\/doi.org\/10.1086\/339543.","journal-title":"Clin Infect Dis."},{"issue":"11","key":"892_CR66","doi-asserted-by":"publisher","first-page":"1770","DOI":"10.1016\/s0149-2918(02)80078-9","volume":"24","author":"N Vetter","year":"2002","unstructured":"Vetter N, Cambronero-Hernandez E, Rohlf J, Simon S, Carides A, Oliveria T, et al. A prospective, randomized, double-blind multicenter comparison of parenteral ertapenem and ceftriaxone for the treatment of hospitalized adults with community-acquired pneumonia. Clin Ther. 2002;24(11):1770\u2013855. https:\/\/doi.org\/10.1016\/s0149-2918(02)80078-9.","journal-title":"Clin Ther"},{"issue":"11","key":"892_CR67","doi-asserted-by":"publisher","first-page":"1856","DOI":"10.1093\/cid\/ciz090","volume":"69","author":"TM File","year":"2019","unstructured":"File TM, Goldberg L, Das A, Sweeney C, Saviski J, Gelone SP, et al. Efficacy and safety of intravenous-to-oral lefamulin, a pleuromutilin antibiotic, for the treatment of community-acquired bacterial pneumonia: the phase III Lefamulin Evaluation Against Pneumonia (LEAP 1) trial. Clin Infect Dis. 2019;69(11):1856\u201367. https:\/\/doi.org\/10.1093\/cid\/ciz090.","journal-title":"Clin Infect Dis"},{"issue":"17","key":"892_CR68","doi-asserted-by":"publisher","first-page":"1661","DOI":"10.1001\/jama.2019.15468","volume":"322","author":"E Alexander","year":"2019","unstructured":"Alexander E, Goldberg L, Das AF, Moran GJ, Sandrock C, Gasink LB, et al. Oral lefamulin vs moxifloxacin for early clinical response among adults with community-acquired bacterial pneumonia: the LEAP 2 randomized clinical trial. JAMA. 2019;322(17):1661\u201371. https:\/\/doi.org\/10.1001\/jama.2019.15468.","journal-title":"JAMA"},{"issue":"7","key":"892_CR69","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1185\/030079902125001191","volume":"18","author":"DJ Van Rensburg","year":"2002","unstructured":"Van Rensburg DJ, Matthews PA, Leroy B. Efficacy and safety of telithromycin in community-acquired pneumonia. Curr Med Res Opin. 2002;18(7):397\u2013400. https:\/\/doi.org\/10.1185\/030079902125001191.","journal-title":"Curr Med Res Opin"},{"issue":"6","key":"892_CR70","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1007\/s15010-002-2096-z","volume":"30","author":"L Hagberg","year":"2002","unstructured":"Hagberg L, Torres A, van Rensburg D, Leroy B, Rangaraju M, Ruuth E. Efficacy and tolerability of once-daily telithromycin compared with high-dose amoxicillin for treatment of community-acquired pneumonia. Infection. 2002;30(6):378\u201386. https:\/\/doi.org\/10.1007\/s15010-002-2096-z.","journal-title":"Infection"},{"issue":"1","key":"892_CR71","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/s0149-2918(04)90005-7","volume":"26","author":"L Mathers Dunbar","year":"2004","unstructured":"Mathers Dunbar L, Hassman J, Tellier G. Efficacy and tolerability of once-daily oral telithromycin compared with clarithromycin for the treatment of community-acquired pneumonia in adults. Clin Ther. 2004;26(1):48\u201362. https:\/\/doi.org\/10.1016\/s0149-2918(04)90005-7.","journal-title":"Clin Ther"},{"issue":"5","key":"892_CR72","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1111\/j.1742-1241.2003.tb10511.x","volume":"57","author":"J Pullman","year":"2003","unstructured":"Pullman J, Champlin J, Vrooman PS Jr. Efficacy and tolerability of once-daily oral therapy with telithromycin compared with trovafloxacin for the treatment of community-acquired pneumonia in adults. Int J Clin Pract. 2003;57(5):377\u201384.","journal-title":"Int J Clin Pract"}],"container-title":["Clinical Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-020-00892-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40262-020-00892-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-020-00892-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,30]],"date-time":"2023-09-30T13:39:55Z","timestamp":1696081195000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40262-020-00892-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4,30]]},"references-count":72,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2020,9]]}},"alternative-id":["892"],"URL":"https:\/\/doi.org\/10.1007\/s40262-020-00892-0","relation":{},"ISSN":["0312-5963","1179-1926"],"issn-type":[{"value":"0312-5963","type":"print"},{"value":"1179-1926","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,4,30]]},"assertion":[{"value":"30 April 2020","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"No sources of funding were used to assist with the preparation of this review.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Anselm Jorda and Markus Zeitlinger have no conflicts of interest that are directly relevant to the content of this review.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}